IVA Inventiva SA

Inventiva reçoit le statut de « Breakthrough Therapy » de la part de la FDA pour lanifibranor, son principal candidat médicament dans la NASH

Inventiva reçoit le statut de « Breakthrough Therapy » de la part de la FDA pour lanifibranor, son principal candidat médicament dans la NASH
EN
12/10/2020

Underlying

IVAInventiva SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Inventiva SA

Mathijs Geerts Danau
  • Mathijs Geerts Danau
IVA INVENTIVA SA

Inventiva FIRST LOOK: preliminary FY25 results hold no surprises

Inventiva reported preliminary FY25 results which hold no surprises, and confirmed its cash-runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to middle of 1Q27. This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We reiterate our Buy rating and € 7 TP.

02/17/26 February 17, 2026 1 EN
Guy Sips ... (+3)
  • Guy Sips
  • Mathijs Geerts Danau
  • Wim Hoste
AGFB AGFA-GEVAERT NV
IVA INVENTIVA SA
DSFIR KONINKLIJKE DSM N.V.
MDXH MDXHEALTH
02/17/26 February 17, 2026 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva reports preliminary 2025¹ fiscal year financial results

Inventiva reports preliminary 2025¹ fiscal year financial results Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the developmen...

February 17, 2026 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva publie ses résultats financiers préliminaires pour l’exercic...

Inventiva publie ses résultats financiers préliminaires pour l’exercice 2025¹ Trésorerie et équivalents de trésorerie à 99,3 millions d’euros, et 131,6 millions d’euros en dépôts à court terme2 au 31 décembre 2025Chiffre d’affaires de 4,5 millions d’euros en 2025Réalisation d’une offre au public aux États-Unis pour un produit brut total d’environ 172,5 millions de dollars (149 millions d’euros)3Horizon de trésorerie prévue jusqu’au milieu du premier trimestre 20274 Daix (France), New York City (New York, Etats-Unis), le 17 février 2026 – (Euronext Paris and Nasdaq :IVA) (« Inventiva » ou ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summi...

Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Daix (France), New York (United States), February 4, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New Yor...

February 4, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch